Continuous Glucose Monitors Now Permitted at UMass Memorial to Monitor Diabetes Patients and Protect Hospital Workers During the COVID-19 Pandemic
About one third of hospital patients have diabetes. Furthermore, more than half of people with diabetes who’ve been diagnosed with the coronavirus have been hospitalized, according to the Centers for Disease Control and Prevention.
The Food and Drug Administration (FDA) decided to allow continuous glucose monitors (CGM) to be used in hospitals during the COVID-19 pandemic. The change was made on a temporary basis to help hospital workers monitor diabetes patients while reducing their own exposure to the coronavirus.
Abbott and Dexcom, two major CGM manufacturers, have donated thousands of their CGM products to hospitals throughout the United States following the FDA’s recent decision. Insulin for Life, a not-for-profit which reallocates unused diabetes supplies to those in need, is helping to distribute the devices to areas hit the hardest by COVID-19.
UMass Memorial Health started using Freestyle 14-day CGMs to monitor blood sugars of patients with diabetes. The devices monitor blood glucose every five minutes and keep track of the results. By utilizing the data produced by the CGMs while patients are hospitalized to receive treatment for COVID-19, the team can deliver better care. It also protects hospital staff from unnecessary exposure to the virus, since the devices can be read from a distance.
"People with diabetes are more likely than those without the disease to require hospitalization for a number of issues that more commonly occur, such as infections, or others that can be more severe, like with COVID-19,” said David Harlan, MD, co-director of the UMass Chan Medical School Diabetes Center of Excellence. “They typically require longer hospital stays than those without diabetes due to the complications that can arise.”